Abeona Therapeutics Achieves Target Enrollment in Pivotal Phase III VIITAL^™ Study of EB-101 in RDEB

Abeona Therapeutics, Inc. announced that target enrollment has been achieved in its pivotal Phase III VIITAL™ study. The objective of VIITAL™ is to evaluate the safety and effectiveness of Abeona’s investigational EB-101 product for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).